azacitidine has been researched along with Bone Marrow Diseases in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Adès, L; Angeli, E; Bally, C; Calleja, A; Chevallier, P; Cluzeau, T; Fenaux, P; Garnier, A; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Gouill, S; Ngo Nloga, AM; Peterlin, P | 1 |
| Dornaus, S; Frietsch, JJ; Hochhaus, A; Kunert, C; La Rosée, P; Neumann, T; Sayer, HG; Schmidt, V; Scholl, S | 1 |
| Harigae, H; Yokoyama, H | 1 |
| Sekeres, MA | 1 |
| Bueso-Ramos, C; Cortes, J; Davis, J; Estrov, Z; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Huang, X; Issa, JP; Kantarjian, H; O'Brien, S; Oki, Y; Ravandi, F; Saba, HI; Shan, J; Wierda, W | 1 |
| Côté, S; Eliopoulos, N; Momparler, RL | 1 |
| Cohen, FB; Custodio, MC; Decter, JA; Lippman, AJ | 1 |
5 review(s) available for azacitidine and Bone Marrow Diseases
| Article | Year |
|---|---|
Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5-azacytidine and literature review.
Topics: Adult; Aged; Anemia, Aplastic; Antimetabolites, Antineoplastic; Autoimmunity; Azacitidine; Bone Marrow; Bone Marrow Diseases; Bone Marrow Failure Disorders; Diagnosis, Differential; Female; Hemoglobinuria, Paroxysmal; Humans; Inflammation; Male; Middle Aged; Myelodysplastic Syndromes; Paraneoplastic Syndromes; Treatment Outcome | 2014 |
[Management of anemia and bone marrow hypoplasia in the treatment of myeloid leukemia].
Topics: Anemia; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Bone Marrow Diseases; Clinical Trials as Topic; Decitabine; Drug Design; Erythrocyte Transfusion; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Platelet Transfusion; Practice Guidelines as Topic | 2009 |
Treatment of MDS: something old, something new, something borrowed...
Topics: Azacitidine; Benzoates; Blood Transfusion; Bone Marrow Diseases; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; DNA-Cytosine Methylases; Glutathione; Hematinics; Humans; Hydrazines; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Risk; Thalidomide; Thrombopoietin | 2009 |
Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Diseases; Cell Differentiation; Decitabine; Deoxycytidine Kinase; DNA Methylation; DNA, Neoplasm; Drug Administration Schedule; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Genes, Tumor Suppressor; Hematopoiesis; Humans; Leukemia | 1997 |
New antineoplastic drugs and their proper use.
Topics: Antineoplastic Agents; Asparaginase; Azacitidine; Bleomycin; Bone Marrow Diseases; Dacarbazine; Doxorubicin; Humans; Liver; Nausea; Neoplasms; Nitrosourea Compounds; Pancreatitis; Pulmonary Fibrosis; Vomiting | 1976 |
1 trial(s) available for azacitidine and Bone Marrow Diseases
| Article | Year |
|---|---|
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Bayes Theorem; Bone Marrow Diseases; Chemical and Drug Induced Liver Injury; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gene Expression Regulation; Gene Expression Regulation, Leukemic; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Remission Induction; Risk; Treatment Outcome | 2007 |
1 other study(ies) available for azacitidine and Bone Marrow Diseases
| Article | Year |
|---|---|
Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients.
Topics: Abnormal Karyotype; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Diseases; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Febrile Neutropenia; Female; France; Hospitalization; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Multicenter Studies as Topic; Myelodysplastic Syndromes; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome | 2020 |